Does Semax increase BDNF?
Semax consistently and significantly increases the expression of BDNF and its protein levels in many brain areas, experimental models, and with various administration routes. This makes the increase in BDNF one of the best-documented and most reproducible mechanisms underlying the neuroprotective and pro-cognitive effects of this peptide.
BDNF, or brain-derived neurotrophic factor, is a protein produced by the brain to maintain nerve cells in good condition, support their growth, strengthen connections between them, and protect them from damage and disease. It can be thought of as the brain's internal repair and maintenance protein.
Evidence for Semax's BDNF-increasing effects includes laboratory cell cultures, living animal brain tissue, and clinical human studies – forming one of the stronger chains of evidence available for the mechanism of action of any synthetic peptide. The magnitude of BDNF increases, the brain regions affected, and how this changes over time have been thoroughly investigated over more than a decade of research. Further consequences, such as activation of the BDNF receptor called TrkB, improvements in synaptic plasticity, and measurable cognitive benefits, have been directly linked to these neurotrophin changes in numerous studies.
How much does Semax increase BDNF? Evidence from animal studies
The magnitude of BDNF increases induced by Semax depends on the tissue type, brain region, and measured time point. However, the fold changes documented in animal studies are significant and pharmacologically relevant.
In rat glial cell cultures – laboratory cultures of supporting brain cells taken from the basal forebrain of newborns – Semax induced an 8-fold increase in BDNF mRNA levels within just 30 minutes of administration [1]. mRNA is a molecular instruction that cells use to produce proteins. An 8-fold increase means that the instructions for BDNF production rose to eight times the normal level. This is one of the fastest and most pronounced effects of neurotrophic gene activation ever documented for any synthetic regulatory peptide.
In live rat hippocampal tissue—the hippocampus being the area of the brain most associated with learning and memory—a single intranasal dose of Semax at 50 micrograms per kilogram of body weight induced a peak 1.4-fold increase in BDNF protein levels. It also induced a 1.6-fold increase in TrkB tyrosine phosphorylation—a chemical change indicating the BDNF receptor was activated and actively delivering BDNF effects inside the cell—along with a 3-fold increase in BDNF mRNA and a 2-fold increase in TrkB mRNA [2]. The molecular changes were accompanied by a measurable improvement in conditioned avoidance learning—a standard behavioral test used to evaluate memory and learning ability in animals—directly linking the molecular changes to actual functional outcomes [2].
Studies tracking BDNF gene activity at multiple time points revealed a more complex and dynamic picture. In the rat hippocampus, BDNF mRNA levels transiently decreased 20 minutes after administration, followed by a significant increase at 90 minutes. In the prefrontal cortex—a brain region responsible for decision-making and complex thought—expression increased early and followed a different temporal pattern. In the eye's retina, a significant increase in BDNF expression was specifically observed at the 90-minute mark [3]. BDNF mRNA levels in the hippocampus peaked around 90 minutes and returned near baseline levels after approximately 8 hours [4]. However, the downstream effects initiated by TrkB receptor activation last considerably longer, through intracellular signaling processes that outlive the BDNF peak itself.
A study that tracked the activity of BDNF and NGF genes at six time points—20 minutes, 40 minutes, 90 minutes, 3 hours, 8 hours, and 24 hours—confirmed that the neurotrophic response to Semax is not a simple, constant increase. It is a dynamic, bidirectional regulation that differs between brain regions and between the two neurotrophin genes [3].
In a rat stroke model where a blood vessel supplying the brain was permanently occluded to simulate ischemic stroke damage, Semax enhanced the activity of the BDNF gene and its receptor TrkC 3 hours after occlusion, and the activity of the NGF gene 24 and 72 hours later [5]. This temporal pattern of neurotrophic gene activation was described as specific to the ischemic context—Semax's effect on neurotrophic gene activity was more pronounced and consistently induced in stroke-affected animals than in healthy ones. This suggests that Semax specifically boosts the brain's natural neurotrophic response to injury, rather than simply inducing a uniform, context-independent effect [5].
In our Alzheimer's disease mouse model, both Semax and a related derivative improved cognitive function in behavioral tests and reduced the number of amyloid plaques – abnormal protein deposits that accumulate in the brain in Alzheimer's disease – in the cortex and hippocampus [6]. These effects are consistent with BDNF-mediated neuroprotection, although the study did not directly measure BDNF levels in this model. In an MPTP neurotoxin-induced Parkinson's disease mouse model – which destroys dopamine-producing neurons in a manner resembling Parkinson's disease – Semax administered before the neurotoxin produced a slight but reliable increase in striatal dopamine levels. The authors interpreted this as evidence that Semax acts primarily by stimulating the brain's own neurotrophic factor production rather than as a direct antioxidant [7], further supporting the induction of neurotrophic factors as the primary mechanism of brain protection.
Does Semax increase BDNF in humans?
Semax increases plasma BDNF levels in human patients after ischemic stroke – those who have suffered a stroke caused by a blocked blood vessel cutting off oxygen supply to part of the brain. This represents the most direct clinical evidence that the mechanism of increasing neurotrophins observed in animals also occurs in humans.
In a study of 110 patients after ischemic stroke, divided into early and late rehabilitation groups, Semax administration—regardless of the rehabilitation start time—significantly increased plasma BDNF levels, which remained elevated throughout the observation period [8]. Plasma BDNF refers to BDNF measured in the liquid part of the blood. In patients who did not receive Semax, high BDNF levels were associated with early initiation of rehabilitation. However, Semax independently increased BDNF regardless of the rehabilitation timing [8].
Crucially, elevated BDNF levels were positively correlated with improved scores on the Barthel Index – a standard clinical tool measuring a person's ability to perform daily activities independently, such as bathing, dressing, and walking – and with a faster return of motor function [8]. This establishes a direct clinical link between Semax-induced BDNF upregulation and significant, actual functional recovery in human patients.
A previous clinical trial of Semax in 30 patients with acute ischemic stroke also demonstrated neurological improvement and recovery of impaired functions, which researchers attributed in part to neuroprotective mechanisms mediated by neurotrophins characterized in parallel animal studies [9]. While plasma BDNF is an indirect measure of BDNF activity within the brain itself, the correlation between its increase and functional recovery outcomes provides significant clinical validation for the BDNF mechanism identified in preclinical studies.
How does Semax affect BDNF in the hippocampus?
Semax influences hippocampal BDNF through a biphasic, time-dependent pattern of gene regulation, ultimately resulting in increased BDNF protein levels and enhanced TrkB receptor activation. As described above, a single intranasal administration of Semax induced a transient early decrease in hippocampal BDNF mRNA at 20 minutes, followed by a significant increase at 90 minutes, with the overall net effect being about a 1.4-fold increase in hippocampal BDNF protein at its peak [2], [3].
Hippocampus-specific regulation of BDNF is particularly important, given the crucial role of this brain region in learning, memory consolidation, spatial navigation – the ability to orient oneself and move in space – and stress regulation. Semax has demonstrated beneficial effects in all these areas. In studies measuring BDNF levels in the hippocampus tissue of mice with different cognitive profiles, Semax specifically increased BDNF levels in the hippocampus of mice that initially had low cognitive performance, without altering BDNF levels in mice with high performance [10]. This suggests that Semax's BDNF-enhancing effect operates preferentially under conditions of relative deficit – meaning it has the greatest impact when BDNF levels are already low – which has significant implications for understanding when and in whom Semax is most likely to provide significant cognitive benefits.
Does Semax increase NGF?
Semax increases the expression of nerve growth factor (NGF) – a protein crucial for the survival and maintenance of nerve cells, especially in brain areas associated with memory and attention. The effects have been documented in many brain regions and experimental models, although the magnitude and timing of NGF increases differ from those related to BDNF and vary significantly depending on the brain region and the measured time point.
In rat glial cell cultures from the basal forebrain, Semax induced a 5-fold increase in NGF mRNA within 30 minutes of administration, with this effect occurring concurrently with a more dramatic 8-fold increase in BDNF at the same time point [1]. In live rat brain tissue following intranasal administration of Semax, NGF gene activity increased in the hippocampus at the 90-minute mark. However, in the frontal cortex, NGF expression exhibited an early decrease before returning to normal levels [3]. This regionally distinct NGF response—an increase in the hippocampus yet an early decrease in the frontal cortex—reflects the complex, region-specific manner in which Semax regulates neurotrophin systems and underscores the importance of analyzing effects in relation to specific brain areas rather than drawing broad, generalized conclusions.
Which studies show that Semax increases NGF expression?
The most detailed characterization of NGF changes induced by Semax was provided by studies tracking gene activity at multiple time points and across multiple brain regions simultaneously. The study by Shadrin et al., analyzing the temporal dynamics of both NGF and BDNF, showed that NGF activity in the retina remained relatively stable in the early period after administration before eventually showing an increase, while hippocampal NGF exhibited a similar biphasic pattern to BDNF [3].
In the context of cerebral ischemia, Semax enhanced NGF gene activity 24 and 72 hours after permanent middle cerebral artery occlusion [5]. This delayed increase in NGF complemented the earlier BDNF response, together providing sustained neurotrophic support signaling during the critical window of stroke recovery. The fact that BDNF responds earlier and more dramatically than NGF may reflect different intrinsic regulatory mechanisms controlling each gene and potentially different functions the two neurotrophins play in acute versus long-term brain protection.
In the basal forebrain of rats, the main source of cholinergic neurons projecting to the hippocampus and cortex, intranasal Semax at a dose of 50 micrograms per kilogram body weight induced measurable increases in BDNF protein levels 3 hours after administration [11]. Cholinergic neurons of the basal forebrain are critically dependent on NGF for their survival. These are also the neurons most affected in Alzheimer's disease. The effect of Semax in increasing NGF in this area is therefore particularly significant for its potential pro-cognitive and anti-dementia properties.
How does Semax affect nerve regeneration?
Nerve regeneration is a process where damaged nerve cells repair themselves, regrow their extensions, and rebuild lost connections. Semax primarily supports nerve regeneration by increasing both BDNF and NGF – two main neurotrophic factors that drive neuron survival, axon growth (regrowth of long extensions by which nerve cells communicate), and synaptic reconnection after injury.
In a spinal cord injury model, Semax promoted functional recovery by interacting with μ-opioid receptors—a type of receptor better known for its role in pain processing—and through a cellular mechanism involving the protein USP18, which regulates how damaged cellular components are broken down and cleared. It also reduced the permeability of lysosomal membranes—the protective walls of the cell's internal waste-processing compartments, the rupture of which causes further damage. Functional outcomes in this model included improved motor scores, normalized gait analysis, and better performance in balance and coordination tests [12].
At the cellular level, Semax increased the proliferative activity – that is, the rate of cell division and multiplication – of neuroglial cells, vascular endothelial cells, and progenitor cells in the periventricular zone of both normal and stroke-affected rat brains [13]. These effects directly support the tissue repair and regeneration processes needed after nervous system injury.
In clinical trials for optic nerve diseases – conditions affecting the nerve that transmits visual signals from the eye to the brain – Semax induced significant improvements in visual acuity, visual field expansion, electrical sensitivity of the eye, and the speed of electrical signal conduction along the optic nerve in patients with vascular, toxic-allergic, and inflammatory optic nerve diseases [14]. These results are consistent with neurotrophic support and partial regeneration of optic nerve fibers. However, these clinical trial designs did not allow for definitive conclusions about which specific neurotrophic mechanisms were responsible, and controlled studies with direct neurotrophin measurements would be needed to establish this link more strongly in humans.
Does Semax promote neuroplasticity?
Semax promotes neuroplasticity through several convergent mechanisms, including by enhancing BDNF and TrkB signaling, strengthening glutamatergic synaptic activity, modulating short-term synaptic plasticity, and activating gene-level pathways related to neurotransmission. Neuroplasticity is the brain's ability to reorganize – strengthening useful connections between nerve cells, weakening unused ones, and creating entirely new ones in response to learning, experience, or injury.
The activation of the hippocampal BDNF/TrkB system by Semax is particularly important here. BDNF-TrkB signaling is considered the main regulator of activity-dependent synaptic plasticity—meaning it controls how effectively synapses are strengthened in response to repeated activity. This process, known as long-term potentiation, is the cellular mechanism most closely underlying learning and memory formation.
In hippocampal slices—thin sections of living hippocampal tissue maintained in the laboratory—Semax at a concentration of 1 micromolar significantly increased the frequency of spontaneous intracellular calcium fluctuations in pyramidal cells of the CA1 field [15]. Intracellular neuronal calcium fluctuations are a direct indicator of cellular activity and synaptic communication. An increase in these fluctuations is consistent with enhanced excitability of the hippocampal network, which underlies plasticity processes.
At the level of individual synapses—the connection points between nerve cells —long-term culture of nerve cells with Semax at concentrations of 10 and 100 micromoles increased the frequency of spontaneous glutamatergic postsynaptic currents to 71.7% and 93.9% above control levels [16]. Semax also increased the quantum of synaptic vesicle release —meaning that each nerve signal triggered the release of a greater amount of neurotransmitter—and modified the parameters of short-term plasticity in a manner consistent with improved efficiency of presynaptic glutamate release [16]. These electrophysiological findings indicate that Semax directly enhances the efficiency of excitatory synaptic transmission, which constitutes the cellular basis for the brain’s strengthening of connections during learning.
In healthy volunteers, resting-state functional MRI – a technique that measures brain activity by detecting changes in blood flow related to neuronal activity – showed that Semax induced a greater volume of activity in a specific part of the default mode network called the rostral component, located in the medial prefrontal cortex, compared to placebo at both 5 and 20 minutes post-administration [17]. The default mode network is a group of brain regions that work together during internally directed thought, self-reflection, and working memory. This discovery provides direct neuroimaging evidence from human studies of altered brain network organization consistent with modified synaptic and circuit-level plasticity.
Does Semax promote neurogenesis?
Semax promotes neurogenesis, with evidence from cell proliferation studies and neonatal administration models indicating its capacity to enhance the production of new neurons and support the activity of neural progenitor cells. Neurogenesis is the process by which the brain produces brand-new nerve cells. Although it was long believed that adult humans could not generate new neurons, research has demonstrated that new nerve cells can form in at least two specific regions of the adult brain: the subventricular zone and the dentate gyrus of the hippocampus.
In rat stroke models, Semax increased cellular proliferation activity in the periventricular zone, as confirmed by histological analysis—microscopic examination of tissue samples. It also increased the proliferation of neuroglial cells and vascular endothelial cells, supporting a broader regenerative environment in the damaged brain [13].
In studies on rat neonates, Semax injections administered on days 7–11 postnatally enhanced neurogenesis in the dentate gyrus of the hippocampus. Effects on seizure susceptibility—specifically, the type of seizures induced by loud sounds—observed in adult animals were attributed, at least in part, to this enhancement of early hippocampal neurogenesis [18]. Direct examination of cell proliferation confirmed that neonatal Semax injection induced measurable changes in cell proliferation in the dentate gyrus region of the hippocampus, with the magnitude of the effect being dependent on the animal's genetic background [19].
These neurogenesis-promoting effects are mechanistically consistent with Semax-induced BDNF increase, as BDNF is one of the most potent known promoters of adult hippocampal neurogenesis. It acts by activating TrkB receptors on neural stem cells in the subgranular zone—a layer just below the dentate gyrus—driving their proliferation, differentiation into mature neurons, and long-term survival.
In studies of catecholaminergic neurons in young mice – neurons producing dopamine and norepinephrine – Semax administration modulated the total number of these neurons in the adult midbrain. This indicates that early exposure to Semax may permanently alter the neuronal composition of specific brain regions through its effects on developmental neurogenesis and neuronal survival [20].
It is worth noting that most evidence regarding neurogenesis for Semax comes from neonatal or injury models, rather than studies of neurogenesis in the healthy adult brain. Whether Semax significantly enhances hippocampal neurogenesis in healthy adult humans under normal physiological conditions has not yet been directly investigated.
How does Semax affect learning and memory at the cellular level?
At the cellular level, Semax enhances learning and memory through several converging mechanisms: increased hippocampal BDNF and TrkB signaling, improved cholinergic neuron function and survival, enhanced glutamatergic synaptic transmission, modulation of intracellular signaling pathways, and activation of gene-level programs related to neurotransmission.
A direct link between Semax-induced changes in BDNF and cognitive outcomes has been established by demonstrating that animals with the highest increases in BDNF and TrkB mRNA in the hippocampus after Semax administration also showed the greatest improvement in a conditional avoidance learning task [2]. In the passive avoidance task – another standard memory consolidation test – intranasal Semax induced greater learning improvement than intraperitoneal injection at equivalent doses, consistent with the nasal route delivering higher concentrations directly to the brain and driving greater hippocampal BDNF increases [21].
At the level of intracellular signal transduction – the chain of molecular events occurring within cells – Semax altered the activity of genes involved in signal transduction pathways in the rat hippocampus, influencing multiple kinase cascades – chains of enzymes that transmit signals within cells – that regulate synaptic strength and memory consolidation [22].
In a model of cerebral cortex stroke, chronic intranasal administration of Semax at a dose of 250 micrograms per kilogram of body weight per day for six days following an experimentally induced stroke led to a complete restoration of spatial learning ability in the Morris water maze—a standard test in which animals must use environmental cues to find a hidden platform in a tank of water. Importantly, this anti-amnestic effect—the reversal of memory loss—persisted long after the treatment course was completed [23]. This suggests that Semax induced a lasting neuroplastic reorganization—long-term structural and functional changes in the brain—rather than merely providing short-term cognitive support.
Protein expression profiling studies—measuring levels of many proteins simultaneously—in a rat stroke model revealed that Semax increased CREB activity in subcortical structures, including the stroke-affected area [24]. CREB is a transcription factor—a protein that turns genes on and off—and is considered the molecular switch most directly responsible for converting synaptic activity into long-term memory storage through changes in gene expression. Concurrently, Semax decreased the activity of MMP-9, c-Fos, and active JNK—proteins associated with inflammation and cellular stress responses [24]. This combination of CREB activation coupled with inflammatory suppression represents a molecular pattern highly consistent with enhanced memory consolidation and neuroprotective plasticity.
Can Semax improve intelligence or increase IQ?
No published studies have assessed the effects of Semax on IQ scores or general intelligence measures in healthy individuals. Claims of cognitive enhancement would go beyond what current scientific evidence supports.
What the research actually shows is that Semax improves specific cognitive areas, including learning speed, memory consolidation, selective attention, and working memory, in animal models and in humans with neurological conditions such as ischemic stroke and cerebrovascular insufficiency.
In healthy volunteers, Semax improved memory and attention under conditions of cognitive load. A 15-year review of its development noted improvements in working memory and selective attention after nasal Semax in both healthy individuals under extreme stress or cognitive load, and in clinical patient populations [25]. Resting-state brain imaging changes observed in healthy individuals suggest that Semax modulates functional connectivity—how well different brain regions communicate with each other—in networks relevant to cognitive function [17]. Observed changes in the default mode network are consistent with effects on internally directed thought, self-referential processing, and working memory.
Whether these measurable improvements in specific cognitive domains translate into significant changes in overall cognitive abilities or intelligence in healthy individuals with normal baseline function remains unknown, as it has not been formally investigated. Available animal evidence suggests that the cognitive benefits of Semax are most pronounced under conditions of cognitive challenge, stress, injury, or initial deficit – rather than through simple enhancement of already optimal cognitive performance. This is consistent with BDNF data showing preferential increase in cognitively impaired mice [10]. The robust scientific answer is: Semax demonstrates true and well-documented effects on learning, memory, and attention in preclinical models and in patients with neurological disorders – whereas whether it significantly improves cognitive outcomes in healthy humans with normal baseline function requires rigorous, placebo-controlled clinical trials that have not yet been published.
Disclaimer
This article is intended solely for educational, informational, and scientific purposes and should not be interpreted as medical advice, a diagnosis, a treatment recommendation, or a claim regarding the efficacy of Semax in the treatment of any medical condition. Semax remains an investigational drug in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article comes from preclinical animal studies and a limited number of clinical trials in humans. Additional, well-designed clinical trials are needed to more accurately determine the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[3] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
Agapova, T. Yu., Agniullin, Ya. V., Silachev, D. N., Shadrina, M. I., Slominsky, P. A., Shram, S. I., Limborskaya, S. A., & Miasoedov, N. F. (2008). Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex. Molecular Genetics, Microbiology, and Virology, (3), 28–32. PMID: 18756821
[5] Dmitrieva, V. G., Povarova, O. V., Skvortsova, V. I., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 30(1), 71–79. https://doi.org/10.1007/s10571-009-9432-0
[6] Radchenko, A. I., Kuzubova, E. V., Apostol, A. A., Mitkevich, V. A., Andreeva, L. A., Limborska, S. A., Stepenko, Yu. V., Shmigerova, V. S., Solin, A. V., Korokin, M. V., Pokrovskii, M. V., Myasoedov, N. F., & Makarov, A. A. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae, 17(4), 110–120. https://doi.org/10.32607/actanaturae.27808
Kolacheva, A. A., & Ugrumov, M. V. (2021). A mouse model of nigrostriatal dopaminergic axonal degeneration as a tool for testing neuroprotectors. Acta Naturae, 13(3), 110–113. https://doi.org/10.32607/actanaturae.11433
Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat’ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in the acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472
Firstova, Yu. Yu., Dolotov, O. V., Kondrakhin, E. A., Dubynina, E. V., Grivennikov, I. A., & Kovalev, G. I. (2009). Effects of nootropic drugs on hippocampal and cortical BDNF levels in mice with different exploratory behavior efficacy. Experimental and Clinical Pharmacology, 72(6), 3–6. PMID: 20095391
[11] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Yu. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax, an analogue of adrenocorticotropin (4-10), specifically binds to and increases brain-derived neurotrophic factor protein levels in the rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
Stavchansky, V. V., Yuzhakov, V. V., Botsina, A. Yu., Skvortsova, V. I., Bondurko, L. N., Tsyganova, M. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: A pilot study. Journal of Molecular Neuroscience, 45(2), 177–185. https://doi.org/10.1007/s12031-010-9421-2
[14] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Ophthalmology Journal, 116(1), 15–18. PMID: 10741256
Kolbaev, S. N., Sharonova, I. N., & Skrebitsky, V. G. (2025). The effect of peptide Semax, an ACTH(4-10) analogue, on intracellular calcium dynamics in rat brain neurons. Bulletin of Experimental Biology and Medicine, 179(4), 416–420. https://doi.org/10.1007/s10517-025-06501-z
[16] Shypshyna, M. S., Veselovsky, N. S., Myasoedov, N. F., Shram, S. I., & Fedulova, S. A. (2015). Effect of peptide Semax on synaptic activity and short-term plasticity of glutamatergic synapses of co-cultured dorsal root ganglion and dorsal horn neurons. Physiological Journal, 61(4), 48–55. https://doi.org/10.15407/fz61.04.048
[17] Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
Timoshenko, T. V., Perepelkina, O. V., Markina, N. V., Revischin, A. V., Pavlova, G. V., Poletaeva, I. I., & Sukhih, G. T. (2009). Audiogenic epilepsy in mice with different genotypes after neonatal treatments enhancing neurogenesis in dentate gyrus. Bulletin of Experimental Biology and Medicine, 147(4), 458–461. https://doi.org/10.1007/s10517-009-0558-3
[19] Timoshenko, T. V., Poletaeva, I. I., Pavlova, G. V., & Revishchin, A. V. (2009). Effect of neonatal injections of the neuropeptide Semax on cell proliferation in hippocampal dentate area in rats of two genotypes. Doklady Biological Sciences, 424, 78–80. https://doi.org/10.1134/s0012496609010232
[20] Boyarshinova, O. S., Revishchin, A. V., Poletaeva, I. I., & Korochkin, L. I. (2004). Neonatal administration of ACTH4-10 and its analog Semax to young laboratory mice modulates the number of catecholaminergic neurons in adult animal diencephalon. Doklady Biological Sciences, 396, 181–183. https://doi.org/10.1023/b:dobs.0000033270.71306.3d
[21] Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Physiological Journal of Russia, 96(10), 1014–1023. PMID: 21268834
Agapova, T. Yu., Agniullin, Ya. V., Silachev, D. N., Shadrina, M. I., Slominsky, P. A., Shram, S. I., Limborskaya, S. A., & Myasoedov, N. F. (2007). Expression changes caused by the peptide semax in the intracellular signal pathway genes in rat hippocampus. Doklady Biochemistry and Biophysics, 417, 334–336. https://doi.org/10.1134/s1607672907060129
Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischemic lesions to the prefrontal cortex; effects of a synthetic analog of ACTH(4-7). Neuroscience & Biobehavioral Reviews(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[24] Sudarkina, O. Yu., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[25] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745